Phathom Pharmaceuticals announces commercial availability of VOQUEZNA

Phathom Pharmaceuticals announced the U.S. commercial availability of VOQUEZNA. VOQUEZNA is now available for the treatment of adults with Erosive Esophagitis, also known as Erosive GERD, and the relief of heartburn associated with Erosive GERD. As the first and only approved potassium-competitive acid blocker in the U.S., this milestone brings the power of a new class of acid suppression treatment to a disease with high unmet need. “We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals. “For over three decades, there has been no major innovation in this category. We are excited to introduce VOQUEZNA to patients and healthcare providers, as it has been shown to provide rapid, potent, and durable acid suppression and has the power to help heal Erosive GERD for patients seeking a new and effective treatment option.”